Valerio Therapeutics · EURONEXT:ALVIO

Valerio Therapeutics — Investor Presentation (October 2025)

13 slides from Valerio Therapeutics's investor presentation, October 2025

  1. Slide 1: The Next-Generation Of Precision-Guided Therapeutics

    Valerio Therapeutics The Next-Generation Of Precision-Guided Therapeutics 2025 | Copyright by Valerio Therapeutics - All Rights Reserved

  2. Slide 2: Specific Tissue Delivery Remains a Major Challenge that Impacts Both Efficacy and Safety

    Valerio Therapeutics Specific Tissue Delivery Remains a Major Challenge that Impacts Both Efficacy and Safety Key Delivery Challenges in Therapeutic Modalities The Boundaries of Delivery Non-specific approaches Delivery limited to few organs Oligo-based Therapies • Tissue Penetration • LNPs • Liver

  3. Slide 3: Single domain Antibodies have been a Major Breakthrough, Unlocking Tissue Delivery

    Valerio Therapeutics Single domain Antibodies have been a Major Breakthrough, Unlocking Tissue Delivery Conventional Antibodies (IgG) 150 kDa Fragments Antigen- Binding (Fab) Camelid-sdAb IgG Fab scFv Peptide 50 kDa Small Size, Tissue Penetration Single-Chain Variable Framents (scFv) Broad diversity

  4. Slide 4: Our V-Body Platform Addresses Some of the Limitations of sdAbs

    Valerio Therapeutics Our V-Body Platform Addresses Some of the Limitations of sdAbs… Conventional Antibodies (IgG) 150 kDa Fragments Antigen- Single domain antibodies Binding (Fab) IgG (sdAb) Fab scFv Peptide (mAb) Camelid- 50 kDa V-Bodies sdAb Small Size, Tissue Penetration Single-Chain Variable Fr

  5. Slide 5: Through Three Unique and Key Attributes

    Valerio Therapeutics … Through Three Unique and Key Attributes Differentiated Proprietary Unparalleled In Vitro State of the Art Platform of Fully Synthetic Selection Process Capabilities Including: V-Body Libraries • V-Bodies • Linker chemistry • Payloads Copyright by Valerio Therapeutics - All Rig

  6. Slide 6: Our Proprietary Platform Allows Significant Time Saving to Generate an Optimal and Customized V-Body

    Valerio Therapeutics Our Proprietary Platform Allows Significant Time Saving to Generate an Optimal and Customized V-Body 1 - 2 Fully synthetic humanized VHH 2 – Proprietary scaffolds with random 3 – Rationale design of CDR regions to create or human VH V-Body libraries CDRs and 4 different lengths

  7. Slide 7: Unparalleled In Vitro Selection Process Allowing for Tailor-Made Functional Binders

    Valerio Therapeutics Unparalleled In Vitro Selection Process Allowing for Tailor-Made Functional Binders V-Select 1 Target selection Target X 2 Swift selection through phage display Panning A fully in vitro process for selecting hundreds of hits from billions of V-Body binders Screening • pH/T° depe

  8. Slide 8: Valerio's Integrated Platform Allows Derisked Lead Candidate in 3 months

    Valerio’s Integrated Platform Allows Derisked Lead Candidate Valerio Therapeutics in 3 months and Development Candidate within 6 to 9 months 2 4 6 8 10 12 14 16 18 20 22 24 Months Semi Synthetic (Ablynx) 14 to 24 months Immune-Library 11 to 21 months Transgenic Mice 10 to 14 months Fully Synthetic (

  9. Slide 9: Harnessing Capabilities; Allowing for a State of the Art Integrated Process from A to Z

    Valerio Therapeutics Harnessing Capabilities; Allowing for a State of the Art Integrated Process from A to Z… V-Body Receptor binding fragments enabling Harnessing 20 years of specific targeting expertise from Institut Curie. Non-cleavable Cleavable Linker Alkyl MCC Synthesis of linker and Bioconjug

  10. Slide 10: Derisking Next-Generation Drug Candidate for FIH in Less than 2 Years

    Valerio Therapeutics … and Derisking Next-Generation Drug Candidate for FIH in Less than 2 Years Delivering derisked drug compound End-use Drug Capabilities Valerio TX Components Customized and Flexible half-life extension An Array of Modalities V-Body Albumin-binding V-body Inhibitor sdAb sdAb-TCE

  11. Slide 11: A Unique Integrated Platform Providing Flexibility to Generate Multi-Modality Leads

    A Unique Integrated Platform Providing Flexibility to Generate Valerio Therapeutics Multi-Modality Leads and Development Candidates In an Unmatched Timeline Fully Synthetic Dual Libraries Optimized Design Time to Lead Flexible & Flexible & (Animal-free) (VH/VHH) (no-PCR, Fully human, Time to DC Inte

  12. Slide 12: Benefits are Already Materialized Through a Diversified Pipeline

    Valerio Therapeutics Benefits are Already Materialized Through a Diversified Pipeline Generating Increasing Interest from Industry Metabolic Diseases Immunology & Inflammatory Oncology Oligonucleotide Payload ADC-like Multi-specific Radionuclide Multi-specific CAR-T V-Bodies conjugates Payload V-Bod

  13. Slide 13: We Aim to Bring Precision-Guided Therapeutics to a New Level

    Valerio Therapeutics We Aim to Bring Precision-Guided Therapeutics to a New Level A team relying on a strong A unique positioning A versatile V-Body based A proven capability to A Strong IP portfolio and complementary to unlock delivery platform offering in deliver derisked IND- 20-years expertise t

Valerio Therapeutics — Investor Presentation (October 2025) on 6ix